• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

FDA Clears AI-Powered Module for Detecting Hemispheric Subdural Hematomas on CT

News
Article

The Rapid SDH module on the RapidAI platform reportedly offers a sensitivity rate of 93 percent for detection of hemispheric subdural hematoma on non-contrast computed tomography (CT) scans.

The Food and Drug Administration (FDA) has granted 510(k) clearance for RapidAI’s Rapid SDH, an artificial intelligence (AI)-enabled module that reportedly notifies radiologists of suspected hemispheric subdural hematomas within one minute of reviewing a computed tomography (CT) scan.

For suspected acute and chronic hemispheric subdural hematomas > 1 mL, the Rapid SDH module offers a sensitivity rate of 93 percent and a specificity rate of 99 percent, according to RapidAI.

In addition to flagging suspected cases of hemispheric subdural hematomas, RapidAI said the Rapid SDH module facilitates multidisciplinary collaboration for the management of these patients via automated notification sent via the RapidAI app, PACS and e-mail.

"The FDA's clearance of Rapid SDH significantly enhances our expanding range of hemorrhagic and trauma care solutions at this crucial time of rapidly growing patient numbers, clinician shortages, and advancements in potential treatment options,” said Amit Phadnis, the chief innovation and technology officer of RapidAI. “Our goal is to continue to expand the capabilities and applications of our deep AI to deliver comprehensive clinical solutions that provide care teams with the crucial insights necessary to evaluate patients, streamline decision making, and expedite care for this common and dangerous disease.”

Related Videos
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Related Content
© 2024 MJH Life Sciences

All rights reserved.